¹⁷⁷Lu-PSMA放射配体治疗用于伴复杂肾脏情况的转移性去势抵抗性前列腺癌:病例系列
本文回顾性描述了6例伴复杂基础肾脏疾病(包括血液透析终末期肾病、肾移植、慢性肾病、肾小球滤过率严重降低、梗阻肾和孤立肾)的mCRPC患者接受¹⁷⁷Lu-PSMA-617 RLT的经验。所有患者至少接受2个周期治疗,4/6例(67%)出现PSA≥50%下降,多数肾功能稳定或改善,无患者因急性肾毒性永久终止治疗。结论认为经仔细筛选、个体化剂量学、多学科协作和密切肾脏监测,该治疗可安全实施。
要点
- 6例伴复杂肾脏疾病的mCRPC患者接受¹⁷⁷Lu-PSMA-617,均至少完成2个周期。
- 4/6例(67%)出现PSA≥50%下降,队列中降幅范围为37%至99.9%。
- 多数肾功能稳定或改善,无患者因急性肾毒性永久终止治疗。
核心结论
- 经仔细患者选择、个体化剂量学、多学科参与和密切肾脏监测,¹⁷⁷Lu-PSMA-617 RLT可在伴复杂肾脏疾病的mCRPC患者中安全实施。
- 这些病例凸显了针对该服务不足人群开展前瞻性数据和制定共识指南的必要性。
研究设计与样本
- 本研究为单中心回顾性病例系列,回顾性审查了接受¹⁷⁷Lu-PSMA-617治疗的伴显著肾脏合并症mCRPC患者病例。
- 共纳入6例具有不同肾脏情况的患者,记录人口学、肾功能参数、治疗调整、剂量学数据、PSA反应和肾脏安全性结局。
主要发现
- 共识别6例具有不同肾脏情况的患者,所有患者至少接受2个周期¹⁷⁷Lu-PSMA-617治疗。
- 4/6例(67%)观察到PSA反应(≥50%下降),队列中降幅范围为37%至99.9%。
- 多数病例肾功能保持稳定或改善,个体化剂量学和多学科管理使安全给药成为可能。
- 无患者因急性肾毒性需要永久终止治疗。
关键数值与推荐
- PSA反应定义为PSA下降≥50%,在4/6例(67%)中观察到,队列降幅范围为37%至99.9%。
临床怎么用
- 对伴复杂肾脏疾病的mCRPC患者,可考虑在仔细选择、个体化剂量学、多学科输入和密切肾功能监测下使用¹⁷⁷Lu-PSMA-617 RLT。
局限性
- 本研究为回顾性病例系列,样本量仅6例,证据级别有限。
- 原文指出该人群通常被排除在临床试验之外,存在显著证据缺口,需要前瞻性数据和共识指南。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: ¹⁷⁷Lu-PSMA-617 radioligand therapy (RLT) is an established treatment for metastatic castration-resistant prostate cancer (mCRPC). Its predominant renal clearance pathway raises concerns about safety and dosimetry in patients with underlying renal disease. Such patients are typically excluded from clinical trials, leaving a significant evidence gap in clinical practice. The aim of this study is to describe our experience with ¹⁷⁷Lu-PSMA-617 RLT in mCRPC patients presenting with complex pre-existing renal conditions, including end-stage renal disease on hemodialysis, renal transplant, chronic kidney disease, severely reduced glomerular filtration rate, obstructed kidneys, and solitary kidney. METHODS: We retrospectively reviewed cases of mCRPC patients with significant renal comorbidity treated with ¹⁷⁷Lu-PSMA-617 at our institution. Patient demographics, renal function parameters, treatment adaptations, dosimetric data, PSA response, and renal safety outcomes were recorded for each case. RESULTS: Six patients with distinct renal conditions were identified. All patients received at least 2 cycles of ¹⁷⁷Lu-PSMA-617. PSA responses (≥50% decline) were observed in 4/6 patients (67%), ranging from 37% to 99.9% across the cohort. Renal function remained stable or improved in most cases, with individualized dosimetry and multidisciplinary management enabling safe administration. No patient required permanent cessation of therapy due to acute renal toxicity. CONCLUSIONS: With careful patient selection, individualized dosimetry, multidisciplinary input, and close renal monitoring, ¹⁷⁷Lu-PSMA-617 RLT can be administered safely in mCRPC patients with complex renal disease. These cases highlight the need for prospective data and consensus guidelines for this underserved population.
引用
- Usmani S, Al Balushi A, Al Saadi S, et al. ¹⁷⁷Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer With Complex Renal Conditions: A Case Series. Clin Nucl Med. 2026. PMID: 42725474. doi:10.1097/RLU.0000000000006689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。